Results Reveal Mechanism of Action and Correlative Analyses Data Results Reveal Mechanism of Action and Correlative Analyses Data
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
